Motus GI Expands Intellectual Property Portfolio with U.S. Patent for the Pure-Vu® System’s Sensing Technology and Suction Control
Rhea-AI Summary
Motus GI Holdings, Inc. has received a new patent (No. 10646108) from the U.S. Patent and Trademark Office, which safeguards its Pure-Vu® System, enhancing endoscopy procedures by improving colon visualization. The Pure-Vu System integrates with standard colonoscopes, facilitating better bowel preparation during colonoscopies, particularly crucial for patients with medical complexities. This innovation addresses significant unmet needs in gastrointestinal care, potentially leading to cost savings and better clinical outcomes, with over 95% success in bowel cleanliness in clinical studies.
Positive
- New patent (No. 10646108) issued for the Pure-Vu System, enhancing intellectual property and competitive advantage.
- The Pure-Vu System improves bowel cleanliness rates over 95% in clinical studies, indicating strong performance.
- Potential for cost savings and improved clinical outcomes, addressing a significant unmet need in gastrointestinal care.
Negative
- None.
News Market Reaction – MOTS
On the day this news was published, MOTS gained 4.67%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
FORT LAUDERDALE, Fla., May 05, 2020 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, today announced that the U.S. Patent and Trademark Office (USPTO) has issued patent No. 10646108 titled “Ancillary vacuum module usable with an endoscope”, which protects the Company’s flagship product – the Pure-Vu® System. The patent covers the integration of Motus GI’s proprietary sensing technology and enhanced suction systems with a colonoscope’s working channel.
“This patent reinforces the continued protection of our Pure-Vu System designed to enable endoscopists to achieve clear visualization of the colon, which we believe may facilitate a quality colonoscopy upon first attempt,” said Tim Moran, chief executive officer of Motus GI. “We continue to grow our intellectual property portfolio, expanding our first mover advantage in the endoscopy space with an innovative platform that can be integrated with a variety of scopes to perform colonoscopies.”
The Pure-Vu System is cleared by the U.S. Food and Drug Administration to help facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure. The device integrates with standard and slim colonoscopes to improve visualization during a colonoscopy while preserving established procedural workflow by irrigating the colon and evacuating debris to provide a better-quality exam. Challenges with bowel preparation for inpatient colonoscopy, particularly patients who are elderly, with comorbidities, or active bleeds, represent a significant area of unmet need that directly affects clinical outcomes and increases the cost of care. Motus GI believes the Pure-Vu System may lead to positive outcomes and lower costs for hospitals by safely and quickly improving visualization of the colon, which we believe may lead to a quality exam the first time. In multiple clinical studies to date, involving the treatment of challenging inpatient and outpatient cases, the Pure-Vu System has consistently helped achieve adequate bowel cleanliness rates greater than
About Motus GI
Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions.
For more information, visit www.motusgi.com and connect with the Company on Twitter, LinkedIn and Facebook.
Forward-Looking Statements
This press release contains certain forward-looking statements. Forward-looking statements are based on the Company's current expectations and assumptions. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms, including without limitation, risks inherent in the development and commercialization of potential products, uncertainty in the timing and results of clinical trials or regulatory approvals, maintenance of intellectual property rights or other risks discussed in the Company’s Form 10-K filed on March 30, 2020 and its other filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Investor Contact:
Bob Yedid
LifeSci Advisors
(646) 597-6989
bob@lifesciadvisors.com
Media Contact:
Gloria Gasaatura
LifeSci Communications
(646) 970-4688
ggasaatura@lifescicommunications.com
FAQ
What is the significance of patent No. 10646108 for MOTS?
How does the Pure-Vu System improve colonoscopy procedures for MOTS?
What are the clinical success rates of the Pure-Vu System?
What market need does MOTS address with its Pure-Vu System?
How might the Pure-Vu System impact healthcare costs?
